Abstract:Introduction Obsessive-compulsive disorder (OCD) is a chronic condition characterized by time-consuming and distressing obsessions and/or compulsions, often accompanied by avoidance behaviours. It is a highly prevalent and incident disorder that results in considerable disability and quality of life reduction. Current pharmacological treatments are hindered by their delayed onset and the limited evidence on how to approach first and second line treatment-resistant patients. Recent research showcased the involvement of glutamatergic pathways in the pathophysiology of OCD prompting research into the potential therapeutic use of ketamine, which binds to the N-methyl-D-aspartic acid receptor and acts as a non-competitive antagonist of glutamate. Objectives The aim of this study is to conduct a literature review on the use of ketamine and its enantiomers as a treatment for OCD and report a clinical case involving an OCD patient who experienced significant improvement following ketamine use. Methods A search was performed on PubMed using a combination of keywords and Medical Subject Headings terms, including "Ketamine", "Esketamine" and "Obsessive-Compulsive Disorder". Only studies that involved patients with OCD aged ≥18 years who had received ketamine or its enantiomers as an intervention and that reported treatment response using a validated scale were included. Results Nine studies were included, 4 case reports, 3 open-label trials and 2 randomized controlled trials, totalling 71 patients. Ketamine was administered intravenously in 7 studies and intranasally in the remaining 2. The results were heterogeneous, with some studies reporting no effect on obsessive-compulsive (OC) symptoms and others demonstrating significant and rapid improvement, albeit some only transitorily. We present the case of a 42-year-old man who experienced OC symptoms since the age of 20 but was only formally diagnosed with OCD 3 years ago. During his first consultation, the patient described obsessive thoughts related to contamination and dirtiness, accompanied by handwashing rituals and avoidance behaviours (e.g., avoiding touching handles and switches). His Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score was 29. Escitalopram was initiated with a progressive dose titration, resulting in partial improvement (Y-BOCS 23). In a follow-up appointment, the patient disclosed that he had purchased and self-administered a single intravenous dose of 2g of ketamine 2 months earlier for recreational use. This led to an immediate and significant improvement of his OC symptoms. Subsequent re-evaluation 4 months later confirmed that he remained asymptomatic (Y-BOCS 2). Conclusions Ketamine may be a therapeutic alternative for OCD patients who are treatment resistant due to its rapid anti-obsessional effect. Further studies with improved designs and larger sample sizes are warranted to better assess the efficacy of ketamine in OCD treatment. Disclosure of Interest None Declared

Benzodiazepines for Treatment-Resistant Major Depressive Disorder and Obsessive-Compulsive Disorder With Comorbid Mega Cisterna Magna

Aripiprazole Augmentation in Managing Comorbid Obsessive-Compulsive Disorder and Bipolar Disorder: a Case with Suicidal Attempts.

Cortico-striato-thalamo-cortical Circuit Abnormalities in Obsessive-Compulsive Disorder: A Voxel-Based Morphometric and Fmri Study of the Whole Brain.

Use of right orbitofrontal repetitive transcranial magnetic stimulation (rTMS) augmentation for treatment-refractory obsessive-compulsive disorder with comorbid major depressive disorder

Comorbid schizophrenia and obsessive compulsive disorder associated with mega cisterna magna: a case report

Effective alleviation of depressive and anxious symptoms and sleep disorders in benzodiazepine-dependent patients through repetitive transcranial magnetic stimulation

Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for the Discontinuation of Long-Term Benzodiazepine Use in Insomnia and Anxiety Disorders

[Repetitive Transcranial Magnetic Stimulation Combined with Antidepressant Medication in Treatment of First-Episode Patients with Major Depression].

Ketamine in the treatment of obsessive-compulsive disorder – a case report and literature review

Neuronavigated Right Orbitofrontal 20 Hz Theta Burst Transcranial Magnetic Stimulation Augmentation for Obsessive–Compulsive Disorder with Comorbid Depression and Anxiety Disorders: An Open-Label Study

Combination of CBT and rTMS: what are the advantages?

[Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder]

Catatonia and melancholia interface: exploring a new paradigm for evaluation and treatment. A case series and literature review

Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study

Do benzodiazepines reduce the efficacy of transcranial magnetic stimulation?

0399 Masked Tapering and Augmented CBTI Improves Benzodiazepine Receptor Agonist Discontinuation in a Randomized Trial

Electrophysiological and Neuropsychological Indices of Cognitive Dysfunction in Patients with Chronic Insomnia and Severe Benzodiazepine Use Disorder

Use of vortioxetine in treating obsessive-compulsive disorder: a case report

Factors associated with the long-term use of benzodiazepine receptor agonists as hypnotics among patients with major depressive disorder and comorbid insomnia

Challenges in the Treatment of Restless Legs Syndrome: A Case Report

Successful treatment of cranial dystonia using a Zolpidem+Melatonin combination: A video case-series